Xanthorrhizol exhibits potent antibacterial activity against Streptococcus mutans; it induces significant ultrastructural abnormalities in Candida species, including cell deformation, surface protrusions, rugged cell surfaces, and clumping; it suppresses TPA-induced ear edema in a dose-dependent manner; it reduces skin tumor multiplicity and incidence in DMBA-initiated and TPA-promoted mouse models; it inhibits ornithine decarboxylase (ODC) expression in mouse epidermis associated with acute inflammation and tumor promotion; and it shows chemopreventive effects against skin carcinogenesis by suppressing hyperplasia and dysplasia progression.